TB is curable — yet the treatment can be punishing. People with TB often take multiple medications daily for several months. Even preventing TB means weeks of pills, taken by people who exhibit no symptoms. The physiological and psychological burden of managing a high volume of daily medication over an extended period can make it harder to finish treatment.
Long-acting technologies (LATs) could change that. Most current LATs for TB under development are injectables — one shot releases medicine slowly over weeks or months, replacing days of pills. Even a single long-acting component in a regimen could cut pill burden, and a single shot for preventive treatment opens the possibility of a pill-free preventative regimen.
The field is still in a nascent stage, with only two long-acting products for TB in clinical trials while several are being tested in animals. But this moment merits recognition because of the possibility it offers. The TB Long-Acting Technologies Pipeline Report shows the next stage of TB science taking shape, and a commitment to making life easier for people with TB.
Because these products are years away, people affected by TB can still shape them, from community advisory boards to early inclusion of pregnant people and children. With existing drugs and novel compounds both being tested for long-acting formulations, the goal is clear — the hardest part of being treated for TB should not be the treatment.
Source : TB CAB
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.